Correlation of the Complement Decay Accelerating Factor, Tumour Necrosis Factors-alpha, and Interleukin-1 Beta with the Response to Rituximab in Rheumatoid Arthritis Patients
DOI:
https://doi.org/10.31351/vol33iss(4SI)pp222-229Keywords:
Response to rituximabAbstract
Rituximab (RTX) is one of the biological medications that has been used in the treatment of autoimmune diseases and cancer. However, a high percentage of patients may experience resistance to RTX therapy. The study aims to investigate the potential association of serum levels of the complement decay accelerating factor (DAF), as well as the pro-inflammatory cytokines, tumour necrosis factor-alpha (TNF-α) and interleukin-1 Beta (IL-1β); with response to RTX treatment in rheumatoid arthritis patients. A cross-sectional study was conducted under specialized physician supervision in the Specialized Center of Rheumatology at Baghdad Teaching Hospital in Baghdad/Iraq. Ninety adult patients who were already diagnosed with rheumatoid arthritis and receiving RTX intravenous infusion, for at least six months, were enrolled in the study. The selected patients were either responders to RTX (45 patients), or non-responders to RTX (45 patients). The response to RTX was assessed according to the 28-joint Disease Activity Score (DAS28). The serum level of the DAF was significantly higher in RTX non-responders in comparison to RTX responders, (P-value ˂0.001). Similarly, serum levels of TNF- α and IL-1β, were significantly higher in RTX non-responders in comparison to RTX responders, (P-value ˂0.001; for each). The serum level of the estimated markers showed a high significant correlation with the 6 months change in DAS28 (P-value ˂0.001; for each). The Cut-off values, sensitivity, and specificity of DAF, TNF-α, and IL-1β in identifying responders to RTX were (≤417.58 µg/L, 97.8%, and 100%), (≤67.69 ng/L, 97.8%, and 100%), and (≤5.38 ng/L, 95.6%, and 95.6%), respectively. In conclusion, serum levels of DAF, TNF-α, and IL-1β have good potential to be used as markers for the assessment of the response to RTX therapy in rheumatoid arthritis patients.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
O'Neil LJ, Alpízar-Rodríguez D, Deane KD. Rheumatoid Arthritis: The Continuum of Disease and Strategies for Prediction, Early Intervention, and Prevention. J Rheumatol. 2024;51(4):337-349.
Faiq MK, Kadhim DJ, Gorial FI. The belief about medicines among a sample of Iraqi patients with rheumatoid arthritis. Iraqi J Pharm Sci. 2019;28(2):134-41.
Gorial FI, Naema SJ, Ali HO, Hussain SA. The influence of rheumatoid arthritis on work productivity among a sample of Iraqi patients. Al-Rafidain Journal of Medical Sciences. 2021;1:110–117.
Black RJ, Cross M, Haile LM, Culbreth GT, Steinmetz JD, Hagins H, et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology. 2023;5(10):e594-e610.
Ding Q, Hu W, Wang R, Yang Q, Zhu M, Li M, et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduction and Targeted Therapy. 2023;8(1):68.
Mohammed SI, Zalzala MH, Gorial FI. The effect of TNF-alpha gene polymorphisms at -376 G/A, -806 C/T, and -1031 T/C on the likelihood of becoming a non-responder to etanercept in a sample of Iraqi rheumatoid arthritis patients. Iraqi J Pharm Sci. 2022;31(2):113-28.
Mutlak QM, Kasim AA, Aljanabi AS. Impact of TYMS gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients - identification of novel single nucleotide polymorphism: Cross-sectional study. Medicine (Baltimore). 2024;103(23):e38448.
Mutlak QM, Kasim AA. Association of the rs1801133 and rs1801131 polymorphisms in the MTHFR gene and the adverse drug reaction of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients. Pharmacia. 2024;71: 1-8.
Naji ZMA, Mohammed SM, Muhammad MF. Uric acid as a natural scavenger of peroxynitrite in a sample of Iraqi patients with rheumatoid arthritis. Iraqi J Pharm Sci. 2012;21(2):51-5.
Alunno A, Carubbi F, Giacomelli R, Gerli R. Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets. BMC rheumatology. 2017;1(1):1-13.
Holers VM, Banda NK. Complement in the initiation and evolution of rheumatoid arthritis. Frontiers in immunology. 2018;9:1057.
Kemper C, Ferreira VP, Paz JT, Holers VM, Lionakis MS, Alexander JJ. Complement: The Road Less Traveled. J Immunol. 2023;210(2):119-125.
Das N, Anand D, Biswas B, Kumari D, Gandhi M. The membrane complement regulatory protein CD59 and its association with rheumatoid arthritis and systemic lupus erythematosus. Current Medicine Research and Practice. 2019;9(5):182-8.
De Boer EC, Van Mourik AG, Jongerius I. Therapeutic lessons to be learned from the role of complement regulators as double-edged sword in health and disease. Frontiers in Immunology. 2020;11:578069.
Karpus ON, Kiener HP, Niederreiter B, Yilmaz-Elis AS, van der Kaa J, Ramaglia V, Arens R, Smolen JS, Botto M, Tak PP, et al. CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis. Arthritis Res Ther 2015;17:6.
Tarkowski A, Trollmo C, Seifert PS, Hansson GK. Expression of decay-accelerating factor on synovial lining cells in inflammatory and degenerative arthritides. Rheumatol Int 1992;12:201–205.
Karpus ON, Heutinck KM, Wijnker PJ, Tak PP, Hamann J. Triggering of the dsRNA sensors TLR3, MDA5, and RIG-I induces CD55 expression in synovial fibroblasts. PLoS One 2012;7:e35606.
Holers VM, Frank RM, Zuscik M, Keeter C, Scheinman RI, Striebich C, Simberg D, Clay MR, Moreland LW, Banda NK. Decay-Accelerating Factor Differentially Associates With Complement-Mediated Damage in Synovium After Meniscus Tear as Compared to Anterior Cruciate Ligament Injury. Immune Netw. 2024;24(2):e17.
Garcia-Montoya L, Villota-Eraso C, Yusof MYM, Vital EM, Emery P. Lessons for rituximab therapy in patients with rheumatoid arthritis. The Lancet Rheumatology. 2020;2(8):e497-e509.
Hassan EF, Kadhim DJ, Younus MM. Safety profile of biological drugs in clinical practice: A retrospective pharmacovigilance study. Iraqi J Pharm Sci. 2022;31(1):32-42.
Gorial FI, Salman S, Abdulazeez ST. Efficacy, safety and predictors of response to rituximab in treatment of Iraqi patients with active rheumatoid arthritis. Al- Anbar Medical Journal. 2019;15(1):16-21.
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-81.
Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, et al. 2016 American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) Criteria for Minimal, Moderate and Major Clinical Response for Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Annals of the rheumatic diseases. 2017;76(5):782.
Shrader J, Popovich J, Gracey G, Danoff J. Navicular Drop Measurement in People With Rheumatoid Arthritis: Interrater and Intrarater Reliability. Physical therapy. 2005;85:656-64.
Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, et al. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis research & therapy. 2005;7:1-9.
Jayakumar K, Norton S, Dixey J, James D, Gough A, Williams P, et al. Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology (Oxford, England). 2012;51(1):169-75.
Jawaheer D, Olsen J, Hetland ML. Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis -- results from the DANBIO registry. The Journal of rheumatology. 2012;39(1):46-53.
Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. The Journal of rheumatology. 2012;39(2):240-6.
Couderc M, Gottenberg JE, Mariette X, Pereira B, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Le Loët X, Shaeverbeke T, Ravaud P, Soubrier M; Club Rhumatismes et Inflammations. Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry. Rheumatology (Oxford). 2014;53(10):1788-93.
Mielnik P, Sexton J, Lie E, Bakland G, Loli LP, Kristianslund EK, et al. Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register. Drugs & aging. 2020;37(8):617-26.
Narvaez J, Díaz-Torné C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, et al. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clinical and experimental rheumatology. 2011;29(6):991-7.
Crouch M, Guesdon W, Shaikh S. Obesity suppresses B cell development and impairs antibody production upon antigen challenge. The FASEB Journal. 2017;31(S1):964.7.
Ottaviani S, Gardette A, Roy C, Tubach F, Gill G, Palazzo E, Meyer O, Dieudé P. Body Mass Index and response to rituximab in rheumatoid arthritis. Joint Bone Spine. 2015;82(6):432-6.
Viecceli D, Garcia MP, Schneider L, Alegretti AP, Silva CK, Ribeiro AL, et al. Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab. Revista brasileira de reumatologia. 2017;57(5):385-91.
Christy JM, Toomey CB, Cauvi DM, Pollard KM. Chapter 25 - Decay-Accelerating Factor. In: Barnum S, Schein T, editors. The Complement FactsBook (Second Edition): Academic Press; 2018. p. 261-70.
Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Annals of the rheumatic diseases. 2008;67(7):917-25.
Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Annals of the rheumatic diseases. 2008;67(3):402-8.
Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, Bruijnen STG, Safy M, Berger FH, et al. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology (Oxford, England). 2019;58(6):1075-85.
Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer research. 2007;67(21):10556-63.
Nicholson-Weller A, March JP, Rosen CE, Spicer DB, Austen KF. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood. 1985;65(5):1237-44.
Makidono C, Mizuno M, Nasu J, Hiraoka S, Okada H, Yamamoto K, et al. Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis. The Journal of laboratory and clinical medicine. 2004;143(3):152-8.
Tchetina EV, Pivanova AN, Markova GA, Lukina GV, Aleksandrova EN, Aleksankin AP, Makarov SA, Kuzin AN. Rituximab Downregulates Gene Expression Associated with Cell Proliferation, Survival, and Proteolysis in the Peripheral Blood from Rheumatoid Arthritis Patients: A Link between High Baseline Autophagy-Related ULK1 Expression and Improved Pain Control. Arthritis. 2016;2016:4963950.
Nasu J, Mizuno M, Uesu T, Takeuchi K, Inaba T, Ohya S, Kawada M, Shimo K, Okada H, Fujita T, Tsuji T. Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol. 1998;113(3):379-85.
Cocuzzi ET, Bardenstein DS, Stavitsky A, Sundarraj N, Medof ME. Upregulation of DAF (CD55) on orbital fibroblasts by cytokines. Differential effects of TNF-beta and TNF-alpha. Curr Eye Res. 2001;23(2):86-92.
Spiller OB, Criado-García O, Rodríguez De Córdoba S, Morgan BP. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin Exp Immunol. 2000;121(2):234-41
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
